We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

103 hedge funds and large institutions have $191M invested in Tetraphase Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

22% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 27

10% more funds holding

Funds holding: 94103 (+9)

7% less capital invested

Capital invested by funds: $204M → $191M (-$13.6M)

52% less call options, than puts

Call options by funds: $840K | Put options by funds: $1.75M

Holders
103
Holders Change
+9
Holders Change %
+9.57%
% of All Funds
2.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
33
Reduced
27
Closed
12
Calls
$840K
Puts
$1.75M
Net Calls
-$915K
Net Calls Change
+$1.41M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$25.5M +$4.53M +35,365 +21%
Millennium Management
2
Millennium Management
New York
$17.1M +$4.09M +31,973 +31%
Canada Pension Plan Investment Board
3
Canada Pension Plan Investment Board
Ontario, Canada
$16.1M
Vanguard Group
4
Vanguard Group
Pennsylvania
$13.2M +$423K +3,305 +3%
NI
5
Numeric Investors
Massachusetts
$12.5M +$242K +1,893 +2%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$8.97M -$247K -1,931 -3%
JP Morgan Chase
7
JP Morgan Chase
New York
$7.36M -$198K -1,546 -3%
Northern Trust
8
Northern Trust
Illinois
$6.4M -$48.7K -380 -0.7%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$6.23M -$1.91M -14,880 -23%
State Street
10
State Street
Massachusetts
$6.03M +$177K +1,381 +3%
RSCM
11
Rock Springs Capital Management
Maryland
$5.99M
BBA
12
Baker Bros. Advisors
New York
$5.89M
BC
13
Broadfin Capital
New York
$5.6M -$69.8K -545 -1%
TCM
14
Tekla Capital Management
Massachusetts
$5.41M
Renaissance Technologies
15
Renaissance Technologies
New York
$3.73M +$1.66M +12,946 +78%
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$3.48M -$264K -2,058 -7%
CS
17
Candriam SCA
Luxembourg
$3.18M +$717K +5,600 +28%
Hudson Bay Capital Management
18
Hudson Bay Capital Management
Connecticut
$3.15M -$384K -3,000 -11%
EAM
19
Eventide Asset Management
Massachusetts
$2.92M
Balyasny Asset Management
20
Balyasny Asset Management
Illinois
$2.77M +$793K +6,195 +39%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$2.69M +$41.6K +325 +2%
Charles Schwab
22
Charles Schwab
California
$1.54M +$171K +1,339 +12%
California Public Employees Retirement System
23
California Public Employees Retirement System
California
$1.53M
Bank of New York Mellon
24
Bank of New York Mellon
New York
$1.48M -$2.82K -22 -0.2%
Deutsche Bank
25
Deutsche Bank
Germany
$1.39M +$890K +6,950 +169%

TTPH Hedge Fund Activity: Q4 2017 in Review

103 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2017, worth a combined $191M — down 6.6% from $204M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new TTPH positions and 12 closed out — a net gain of 10 holders — while 33 added to existing stakes and 27 trimmed.

The largest buyer was BlackRock, adding an estimated $4.53M. The largest seller was Wellington Management Group, exiting entirely with an estimated $11.5M sold.

  • 103 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2017, up from 94 in Q3 2017.
  • Funds reported $191M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2017, down 6.6% quarter-over-quarter.
  • 22 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2017 and 12 closed out, a net change of +10 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2017 was BlackRock, an estimated $4.53M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2017 was Wellington Management Group, an estimated $11.5M sold.

Based on aggregated 13F filings for Q4 2017.